Skip to main content
Top
Published in: Archives of Virology 10/2012

01-10-2012 | Brief Report

Molecular epidemiology of hepatitis C virus among injection drug users in Iran: a slight change in prevalence of HCV genotypes over time

Authors: Katayoun Samimi-Rad, Mohsen Nasiri Toosi, Ali Masoudi-nejad, Ali Najafi, Ramin Rahimnia, Fatemeh Asgari, Alireza Namazi Shabestari, Gholamreza Hassanpour, Seyed-Moayed Alavian, Freshteh Asgari

Published in: Archives of Virology | Issue 10/2012

Login to get access

Abstract

Injecting drug users (IDUs) are the main at-risk population for hepatitis C virus (HCV) transmission. We studied HCV infection, risk factors, and genotype distribution in relation to the year of first injection among Iranian IDUs. Of a total of 126 specimens positive for HCV antibody, 93 (74 %) had detectible HCV RNA, and the NS5B gene was sequenced for 83, with genotype 3a (n = 48, 58 %) being predominant, followed by 1a (n = 35, 42 %). Tattooing was an independent predictor for HCV infection. No significant difference was found between HCV genotypes and IDU characteristics. Although there was no change in the distribution of prevalent genotypes before and after 1997, a slight variation in the prevalence was observed (p = 0.71). The difference in the prevalence of subtypes 1a and 3a (9.1 % in the period 1984-1996 and 18.2 % in the period 1997-2009) during 25 years was 9.1 %. These findings indicate a high prevalence of HCV infection among Iranian IDUs and highlights HCV-3a as the most prevalent subtype for the past 25 years. Harm-reduction strategies appear to be the most important measures to reduce the transmission of HCV in Iran.
Literature
1.
go back to reference Rezvan H, Abolghassemi H, Kafiabad SA (2007) Transfusion-transmitted infections among multitransfused patients in Iran: a review. Transfusion Med 17:425–433CrossRef Rezvan H, Abolghassemi H, Kafiabad SA (2007) Transfusion-transmitted infections among multitransfused patients in Iran: a review. Transfusion Med 17:425–433CrossRef
2.
go back to reference Zamani S, Radfar R, Nematollahi P, Fadaie R, Meshkati M, Mortazavi S, Sedaghat A, Ono-Kihara M, Kihara M (2010) Prevalence of HCV /HIV /HBV infections and drug–related risk behaviours amongst IDUs recruited through peer–driven sampling in Iran. Int J Drug policy 21:493–500PubMedCrossRef Zamani S, Radfar R, Nematollahi P, Fadaie R, Meshkati M, Mortazavi S, Sedaghat A, Ono-Kihara M, Kihara M (2010) Prevalence of HCV /HIV /HBV infections and drug–related risk behaviours amongst IDUs recruited through peer–driven sampling in Iran. Int J Drug policy 21:493–500PubMedCrossRef
3.
go back to reference Kheirandish P, Seyed Alinaghi S, Jahani M, Shirzad H, Seyed Ahmadian M, Majidi A, Sharifi A, Hosseini M, Mohraz M, McFarland W (2009) Prevalence and correlates of hepatitis C infection among male injection drug users in detention, Tehran, Iran. J Urban Health 86:902–908PubMedCrossRef Kheirandish P, Seyed Alinaghi S, Jahani M, Shirzad H, Seyed Ahmadian M, Majidi A, Sharifi A, Hosseini M, Mohraz M, McFarland W (2009) Prevalence and correlates of hepatitis C infection among male injection drug users in detention, Tehran, Iran. J Urban Health 86:902–908PubMedCrossRef
4.
go back to reference Zali MR, Nowroozi A, Amir-rasooly H, Darvishi M (1998) Prevalence of anti HCV antibody and routes of hematological transmission addicts of Ghasr prison [in Persian]. Pajouhesh 22:26–32 Zali MR, Nowroozi A, Amir-rasooly H, Darvishi M (1998) Prevalence of anti HCV antibody and routes of hematological transmission addicts of Ghasr prison [in Persian]. Pajouhesh 22:26–32
5.
go back to reference Zamani S, Ichikawa S, Nassiri manesh B, Vazirian M, Ichikawa K, Gouya MM, Afshar P, Ono-Kihara M, Mortazavi Ravari S, Kihara M (2007) Prevalence and correlates of HCV infection among injecting drug users in Tehran. Int J Drug policy 18:359–363PubMedCrossRef Zamani S, Ichikawa S, Nassiri manesh B, Vazirian M, Ichikawa K, Gouya MM, Afshar P, Ono-Kihara M, Mortazavi Ravari S, Kihara M (2007) Prevalence and correlates of HCV infection among injecting drug users in Tehran. Int J Drug policy 18:359–363PubMedCrossRef
6.
go back to reference Mohamad Alizadeh AH, Alavian SM, Jafari K, Yazdi N (2005) Prevalence of HCV infection and its related risk factors in drug abuser prisoners in Hamedan –Iran. World J Gastroenterol 11:4085–4089 Mohamad Alizadeh AH, Alavian SM, Jafari K, Yazdi N (2005) Prevalence of HCV infection and its related risk factors in drug abuser prisoners in Hamedan –Iran. World J Gastroenterol 11:4085–4089
7.
go back to reference Asgari F, Gooya MM, Mohammad K, Fotouhi A, Yousefi A (2008) Hepatitis C virus infection among Iranian prisoners and its relation with addiction, 2001–2005 [in Persian]. Hakim 11:1–8 Asgari F, Gooya MM, Mohammad K, Fotouhi A, Yousefi A (2008) Hepatitis C virus infection among Iranian prisoners and its relation with addiction, 2001–2005 [in Persian]. Hakim 11:1–8
8.
go back to reference Khani M, Vakili M-M (2003) Prevalence and risk factors of HIV, Hepatitis B virus and Hepatitis C virus infections in Drug addicts among Zanjan prisoners. Arch Iranian Med 6:1–4 Khani M, Vakili M-M (2003) Prevalence and risk factors of HIV, Hepatitis B virus and Hepatitis C virus infections in Drug addicts among Zanjan prisoners. Arch Iranian Med 6:1–4
9.
go back to reference Rowhani Rahbar A, Rooholamini S, Khoshnood K (2004) Prevalence of HIV infection and other blood borne infections in incarcerated and non-incarcerated injection drug users IVDUs in Mashhad. Iran. Int J Drug Policy 15:151–155CrossRef Rowhani Rahbar A, Rooholamini S, Khoshnood K (2004) Prevalence of HIV infection and other blood borne infections in incarcerated and non-incarcerated injection drug users IVDUs in Mashhad. Iran. Int J Drug Policy 15:151–155CrossRef
10.
go back to reference Mohtasham Amiri Z, Rezvani M, Jafari shakib R, Jafari shakib A (2007) Prevalence of HCV infection and risk factors of drug using prisoners in Guilan province. EMHJ 13:250–256 Mohtasham Amiri Z, Rezvani M, Jafari shakib R, Jafari shakib A (2007) Prevalence of HCV infection and risk factors of drug using prisoners in Guilan province. EMHJ 13:250–256
11.
go back to reference Micalessi MI, Gerard C, Ameye L, Palasschaert B, Brochier B, Vranckx R (2008) Distribution of hepatitis C virus genotypes among injecting drug users in contact with treatment centers in Belgium, 2004–2005. J Med Virol 80:640–645PubMedCrossRef Micalessi MI, Gerard C, Ameye L, Palasschaert B, Brochier B, Vranckx R (2008) Distribution of hepatitis C virus genotypes among injecting drug users in contact with treatment centers in Belgium, 2004–2005. J Med Virol 80:640–645PubMedCrossRef
12.
go back to reference Dal Molin G, Ansaldi F, Biagi C, D′Agro P, Comar M, Croce L, Tiribelli C, Campello C (2002) Changing molecular epidemiology of hepatitis C virus infection in Northeast Italy. J Med Virol 68:352–356PubMedCrossRef Dal Molin G, Ansaldi F, Biagi C, D′Agro P, Comar M, Croce L, Tiribelli C, Campello C (2002) Changing molecular epidemiology of hepatitis C virus infection in Northeast Italy. J Med Virol 68:352–356PubMedCrossRef
13.
go back to reference Samimi-Rad K, Shahbaz B (2007) Hepatitis C virus genotypes among patients with thalassemia and inherited bleeding disorders in Markazi province. Iran. Haemophilia 13:156–163CrossRef Samimi-Rad K, Shahbaz B (2007) Hepatitis C virus genotypes among patients with thalassemia and inherited bleeding disorders in Markazi province. Iran. Haemophilia 13:156–163CrossRef
14.
go back to reference Hosseini-Moghaddam SM, Keyvani H, Kasiri H, Kazemeyni SM, Basiri A, Aghel N, Alavian SM (2006) Distribution of hepatitis C virus genotypes among hemodialysis patients in Tehran–a multicenter study. J Med Virol 78:569–573PubMedCrossRef Hosseini-Moghaddam SM, Keyvani H, Kasiri H, Kazemeyni SM, Basiri A, Aghel N, Alavian SM (2006) Distribution of hepatitis C virus genotypes among hemodialysis patients in Tehran–a multicenter study. J Med Virol 78:569–573PubMedCrossRef
15.
go back to reference Alavian SM, Miri SM, Keshvari M, Elizee PK, Behnava B, Tabatabaei SV, Lankarani KB (2009) Distribution of hepatitis C virus genotype in Iranian multiply transfused patients with thalassemia. Transfusion 49:2195–2199PubMedCrossRef Alavian SM, Miri SM, Keshvari M, Elizee PK, Behnava B, Tabatabaei SV, Lankarani KB (2009) Distribution of hepatitis C virus genotype in Iranian multiply transfused patients with thalassemia. Transfusion 49:2195–2199PubMedCrossRef
16.
go back to reference Samimi-Rad K, Nategh R, Malekzadeh R, Norder H, Magnius L (2004) Molecular of epidemiology of Hepatitis C virus in Iran as reflected by phylogenetic analysis of the NS5B region. J Med Virol 74:246–252PubMedCrossRef Samimi-Rad K, Nategh R, Malekzadeh R, Norder H, Magnius L (2004) Molecular of epidemiology of Hepatitis C virus in Iran as reflected by phylogenetic analysis of the NS5B region. J Med Virol 74:246–252PubMedCrossRef
17.
go back to reference Kimura M (1980) A simple method for estimating evolutionary rate of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 16:111–120PubMedCrossRef Kimura M (1980) A simple method for estimating evolutionary rate of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 16:111–120PubMedCrossRef
18.
go back to reference Sereno S, Perinelli P, Laghi V (2009) Changes in the prevalence of hepatitis C virus genotype among Italian injection drug users-relation to period of injection started. J Clin Virol 45:354–357PubMedCrossRef Sereno S, Perinelli P, Laghi V (2009) Changes in the prevalence of hepatitis C virus genotype among Italian injection drug users-relation to period of injection started. J Clin Virol 45:354–357PubMedCrossRef
19.
go back to reference Kabir A, Alavian SM, Keyvani H (2006) Distribution of hepatitis C virus genotypes in patients infected by different sources and its correlation with clinical and virological parameters: a preliminary study. Comp Hepatol 5:4PubMedCrossRef Kabir A, Alavian SM, Keyvani H (2006) Distribution of hepatitis C virus genotypes in patients infected by different sources and its correlation with clinical and virological parameters: a preliminary study. Comp Hepatol 5:4PubMedCrossRef
20.
go back to reference Paintsil E, Verevochkin SV, Dukhovlinova E, Niccolai L, Barbour R, White E, Toussova OV, Alexander L, Kozlov AP, Heimer R (2009) Hepatitis C virus infection among drug injectors in St. Petersburg, Russia: social and molecular epidemiology of an endemic infection. NIH 104:1881–1890 Paintsil E, Verevochkin SV, Dukhovlinova E, Niccolai L, Barbour R, White E, Toussova OV, Alexander L, Kozlov AP, Heimer R (2009) Hepatitis C virus infection among drug injectors in St. Petersburg, Russia: social and molecular epidemiology of an endemic infection. NIH 104:1881–1890
21.
go back to reference Demetriou VL, van de Vijver DA, Hezka J, Kostrikis LG; Cyprus IVDU Network, Kostrikis LG (2010) Hepatitis C infection among intravenous drug users attending therapy programs in Cyprus. J Med Virol 82:263–270 Demetriou VL, van de Vijver DA, Hezka J, Kostrikis LG; Cyprus IVDU Network, Kostrikis LG (2010) Hepatitis C infection among intravenous drug users attending therapy programs in Cyprus. J Med Virol 82:263–270
22.
go back to reference Abolghassemi H, Amid A, Zeinali S, Radfar MH, Eshghi P, Rahiminejad MS, Ehsani MA, Najmabadi H, Akbari MT, Afrasiabi A, Akhavan-Niaki H, Hoorfar H (2007) Thalassemia in Iran: epidemiology, prevention, and management. J Pediat Hematol Onc 29:233–238CrossRef Abolghassemi H, Amid A, Zeinali S, Radfar MH, Eshghi P, Rahiminejad MS, Ehsani MA, Najmabadi H, Akbari MT, Afrasiabi A, Akhavan-Niaki H, Hoorfar H (2007) Thalassemia in Iran: epidemiology, prevention, and management. J Pediat Hematol Onc 29:233–238CrossRef
23.
go back to reference Zali MR, Aghazadeh R, Noroozi A, Amirrasooli H (2001) Anti-HCV antibody among Iranian IV drug users: is it a serious problem? Arch Iranian Med 4:115–119 Zali MR, Aghazadeh R, Noroozi A, Amirrasooli H (2001) Anti-HCV antibody among Iranian IV drug users: is it a serious problem? Arch Iranian Med 4:115–119
24.
go back to reference Hickman M, Hope V, Brady T, Madden P, Jones S, Honor S, Holloway G, Ncube F, Parry J (2007) Hepatitis C virus (HCV) prevalence and injecting risk behaviour in multiple sites in England in 2004. J Viral Hepatitis 14:645–652CrossRef Hickman M, Hope V, Brady T, Madden P, Jones S, Honor S, Holloway G, Ncube F, Parry J (2007) Hepatitis C virus (HCV) prevalence and injecting risk behaviour in multiple sites in England in 2004. J Viral Hepatitis 14:645–652CrossRef
25.
go back to reference Esteban J, Sauleda S, Quer J (2008) The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 48:148–162PubMedCrossRef Esteban J, Sauleda S, Quer J (2008) The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 48:148–162PubMedCrossRef
26.
go back to reference Kalilina O, Norder H, Vetrov T, Zhdanov K, Barzunova M, Plotnikova V, Mukomolov S, Magnius LO (2001) Shift in predominating subtype of HCV from 1b to 3a in St. Petersburg mediated by increase in injecting drug use. J Med Virol 65:517–524CrossRef Kalilina O, Norder H, Vetrov T, Zhdanov K, Barzunova M, Plotnikova V, Mukomolov S, Magnius LO (2001) Shift in predominating subtype of HCV from 1b to 3a in St. Petersburg mediated by increase in injecting drug use. J Med Virol 65:517–524CrossRef
Metadata
Title
Molecular epidemiology of hepatitis C virus among injection drug users in Iran: a slight change in prevalence of HCV genotypes over time
Authors
Katayoun Samimi-Rad
Mohsen Nasiri Toosi
Ali Masoudi-nejad
Ali Najafi
Ramin Rahimnia
Fatemeh Asgari
Alireza Namazi Shabestari
Gholamreza Hassanpour
Seyed-Moayed Alavian
Freshteh Asgari
Publication date
01-10-2012
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 10/2012
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-012-1369-9

Other articles of this Issue 10/2012

Archives of Virology 10/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.